What is Lifesci Capital’s Estimate for KALA BIO Q3 Earnings?

KALA BIO, Inc. (NASDAQ:KALA) – Analysts at Lifesci Capital dropped their Q3 2025 earnings estimates for KALA BIO in a research report issued on Monday, September 29th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($1.88) for the quarter, down from their previous estimate of ($1.02). Lifesci Capital currently has a “Hold” rating on the stock. The consensus estimate for KALA BIO’s current full-year earnings is ($10.84) per share. Lifesci Capital also issued estimates for KALA BIO’s Q4 2025 earnings at ($1.44) EPS, FY2025 earnings at ($6.44) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.24) EPS.

Other equities analysts have also issued research reports about the company. Oppenheimer boosted their price objective on KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. LADENBURG THALM/SH SH lowered KALA BIO from a “buy” rating to a “neutral” rating in a report on Monday. Mizuho set a $1.50 price objective on shares of KALA BIO in a report on Tuesday. HC Wainwright restated a “neutral” rating on shares of KALA BIO in a research report on Monday. Finally, Wall Street Zen lowered shares of KALA BIO from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.38.

KALA BIO Price Performance

KALA stock opened at $1.54 on Wednesday. KALA BIO has a 1 year low of $1.10 and a 1 year high of $20.60. The company has a debt-to-equity ratio of 3.19, a current ratio of 2.10 and a quick ratio of 2.10. The firm has a market capitalization of $10.81 million, a PE ratio of -0.23 and a beta of -2.10. The business has a 50 day simple moving average of $11.03 and a 200-day simple moving average of $6.77.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings data on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating analysts’ consensus estimates of ($1.82) by $0.11.

Insider Transactions at KALA BIO

In other KALA BIO news, major shareholder Bros. Advisors Lp Baker sold 513,607 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $1.38, for a total transaction of $708,777.66. Following the transaction, the insider directly owned 46,480 shares in the company, valued at $64,142.40. This represents a 91.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.32% of the stock is currently owned by insiders.

Hedge Funds Weigh In On KALA BIO

Several hedge funds have recently bought and sold shares of KALA. XTX Topco Ltd acquired a new position in KALA BIO in the 2nd quarter valued at about $62,000. Geode Capital Management LLC grew its holdings in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after purchasing an additional 1,534 shares in the last quarter. AIGH Capital Management LLC increased its stake in KALA BIO by 52.8% during the 2nd quarter. AIGH Capital Management LLC now owns 300,000 shares of the company’s stock worth $1,428,000 after buying an additional 103,650 shares during the period. Woodline Partners LP acquired a new stake in KALA BIO during the 1st quarter worth approximately $1,483,000. Finally, ADAR1 Capital Management LLC lifted its holdings in KALA BIO by 35.7% during the 1st quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock worth $1,713,000 after buying an additional 78,582 shares in the last quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.